Mycobacterial proteins, microorganisms producing them and their use for vaccines and for the detection of tuberculosis

• US 6,676,945 B2
• Filed: 11/02/2001
• Issued: 01/13/2004
• Est. Priority Date: 02/01/1995
• Status: Expired due to Fees

• Current Assignee: Institut Pasteur
• Original Assignee: Institut Pasteur
• Inventors: Marchal, Gilles, Romain, Felix, Pescher, Pascale, Laqueyrerie, Anne
• Primary Examiner(s): Graser, Jennifer E.
• Application Number:
  US09/985,372
• Publication Number:
  US 20030054008A1
• Time in Patent Office: 802 Days
• Field of Search: 530/350, 530/395, 424/185.1, 424/190.1, 424/192.1, 424/197.11, 424/201.1, 424/203.1, 424/193.1, 424/204.1, 424/217.1, 424/227.1, 424/258.1, 424/245.1
• US Class Current: 424/192.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: C07K 14/35 from Mycobacteriaceae (F)
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: Y10S 435/975 Kit

Abstract

Mycobacterium tuberculosis protein having a molecular weight of 28.779 Da, and hybrid proteins containing at least portions of its sequence.

These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.

Claims

1. A hybrid protein, comprising the amino acid sequence of SEQ ID NO:

2 or SEQ ID NO;

3 linked to an antigenic polypeptide which is able to induce an immune response in an animal.

2. The hybrid protein of claim 1, comprising the amino acid sequence of SEQ ID NO:

2 and a linked to an antigenic polypeptide which is able to induce an immune response in an animal.

3. The hybrid protein of claim 1, comprising the amino acid sequence of SEQ ID NO:

3 linked to an antigenic polypeptide which is able to induce an immune response in an animal.

4. The hybrid protein of claim 1, wherein the immune response is a humoral immune response.

5. The hybrid protein of claim 1, wherein the immune response is a cellular immune response.

6. The hybrid protein of claim 1, wherein said antigenic polypeptide is a glycoprotein.

7. The hybrid protein of claim 1, wherein said antigenic polypeptide is a viral toxin.

8. The hybrid protein of claim 1, wherein said antigenic polypeptide is selected from the group consisting of a diphtheria toxin, a tetanus toxin, an HBS antigen of the HBV virus, and a VP1 antigen of the poliomyelitis virus.

9. A composition comprising the hybrid protein of claim 1.

10. A pharmaceutical composition comprising a pharmaceutically effective amount of the hybrid protein of claim 1 and a pharmaceutically compatible diluent or adjuvant.

11. A method of inducing an immune response in an animal, comprising administering the hybrid protein of claim 1 to said animal in an amount effective to induce an immune response.

12. The method of claim 11, wherein said animal is a human.